Bristol Myers Squibb

REVLIMID is a prescription medicine containing lenalidomide, presented on an official patient website for US audiences. The site explains its use in adults with multiple myeloma, in combination with dexamethasone, and as maintenance treatment after an autologous stem cell transplant. It also lists other indications, including myelodysplastic syndromes, mantle cell lymphoma, and follicular and marginal zone lymphoma. REVLIMID should not be used for chronic lymphocytic leukemia except in a controlled clinical trial, and its safety and effectiveness in children are not known.

The website provides information about taking REVLIMID, maintenance therapy, possible serious and common side effects, and the Lenalidomide REMS program, which patients must follow. It also offers educational videos, frequently asked questions, a glossary, downloadable resources, patient stories, caregiver information, and guidance about living with multiple myeloma. Bristol Myers Squibb is identified as offering BMS Access Support to help patients access prescribed medicines. The site encourages patients to discuss treatment with their healthcare provider and directs them to prescribing and safety information.